Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of the Cosmetic Product "Onco-Repair" on Grade 2 Hand Foot Syndrome (OCRP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03612011
Recruitment Status : Completed
First Posted : August 2, 2018
Last Update Posted : September 6, 2019
Sponsor:
Collaborator:
NAOS
Information provided by (Responsible Party):
Quanta Medical

Brief Summary:
The aim of the study is to assess the restorative efficacy of the cosmetic product "Onco-Repair" vs placebo of the most affected palmer face in subject with grade 2 HFS induced by targeted therapies or conventional chemotherapy.

Condition or disease Intervention/treatment Phase
Grade 2 Hand-foot Syndrom Other: Onco-Repair/ Placebo Phase 3

Detailed Description:

HFS, also known as Palmar-Plantar Erythrodysethesia, is a common adverse event observed in subjects under anti-tumor therapy with conventional chemotherapy or targeted thérapies. The initial symptoms are dysesthesia and tingling in the palms, fingers and soles of feet and erythema, which may progress to burning pain with dryness, cracking, desquamation, ulceration and oedema. Sensory impairment, paresthesia and pruritus have also been reported. Palms of the hands are more frequently affected than soles of the feet, and might even be the only area affected in some subjects.

Although HFS is rarely life-threatening, the skin changes are often painful and debilitating and can impair with the general activities of daily living and quality of life. No standard prevention for HFS has not been established yet.

Onco-Repair is a nourishing and repairing cream specially formulated to treat grade 2 HFS which demonstrate skin tolerance, hypoallergenicity and efficacy through several preclinical and clinical studies on healthy subjects.

Therefore, a randomized, double-blind, placebo-controlled study will be conducted to evaluate efficacy and safety of topical cream 'Onco-Repair' on HFS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase III multicenter, double blind, superiority, prospective, randomised controlled study Subjects will be randomized to receive either cosmetic product "Onco-Repair" or placebo in a 1:1 ratio
Masking: Double (Participant, Investigator)
Masking Description: Cosmetic product "Onco-Repair" and placebo will be filled in the tubes with same appearance and smell. The tubes will be marked anonymusioly
Primary Purpose: Treatment
Official Title: Evaluation of the Restorative Efficacy of the Cosmetic Product "Onco-Repair" vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo.
Actual Study Start Date : July 12, 2018
Actual Primary Completion Date : August 1, 2018
Actual Study Completion Date : June 2, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Onco-Repair
Onco-Repair tube of 150 ml
Other: Onco-Repair/ Placebo
Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.

Placebo Comparator: Placebo
Placebo tube of 150 ml
Other: Onco-Repair/ Placebo
Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.




Primary Outcome Measures :
  1. Overall success [ Time Frame: 28 days ]

    A subject is considered to have attained success if he achieves at least one grade improvement in HFS for the most affected palmer face according to the National Cancer Institute CTCATE V5.0 at any time during study period (28 days).

    The subjects will be defined in success or failure according to the following rules:

    Success: switch from grade 2 to grade 1 or grade 0 Failure: switch from grade 2 to grade 3 If subjects remain at grade 2 at the end of the study, they will be classified as either success or failure according to the evolution of clinical signs and / or quality of life assessed using the Dermatological Life Quality Index (DLQI) scale from D0 to D28.



Secondary Outcome Measures :
  1. Time to onset of grade 1 or 0 will be assessed using time (in days) from study commencement (inclusion, D0) to first occurrence of grade 1 or lower HFS according to the CTCAEV5.0 [ Time Frame: 28 days ]
    Time to onset of grade 1 or 0 will be assessed using time (in days) from study

  2. Clinical parameters such as lesion color [ Time Frame: Day 0 (inclusion) , Day 7 and Day 28 ]

    Clinical parameters such as lesion color will be assessed

    • On e-CRF at D0, D7 and D28
    • from D0 to D28 using a standardized diary completed by subjects

  3. Clinical parameters such as presence of blisters [ Time Frame: Day 0 (inclusion) , Day 7 and Day 28 ]

    Clinical parameters such as presence of blisters will be assessed

    • On e-CRF at D0, D7 and D28
    • from D0 to D28 using a standardized diary completed by subjects

  4. Clinical parameters such as fissures/cracks [ Time Frame: Day 0 (inclusion) , Day 7 and Day 28 ]

    Clinical parameters such as fissures/cracks will be assessed

    • On e-CRF at D0, D7 and D28
    • from D0 to D28 using a standardized diary completed by subjects

  5. Assessment of quality of life from D0 to D28 using Dermatology Life Quality Index scale [ Time Frame: 28 days ]

    Quality of life will be assessed from D0 to D28 using Dermatology Life Quality Index scale. It is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages.

    Meaning of Dermatology Life Quality Index scale Scores:

    0 to 1 = no effect at all on patient's life 2 to 5 = small effect on patient's life 6 to 10 = moderate effect on patient's life 11 to 20 = very large effect on patient's life 21 to 30 = extremely large effect on patient's life


  6. Assessment of symptoms [ Time Frame: Day 0 (inclusion) , Day 7 and Day 28 ]
    Such as intensity of lesions, feeling of subjects, etc will be assessed: on e-CRF at D0, D7 and D28, from D0 to D28 using a standardized diary completed by subjects

  7. Assessment of pain score and prurit at D0, D7 and D28 using a 100 Visual Analogue Scale [Visual analogue scale, 0 (no pain, no prurit) and 100 (worst possible pain or prurit)] [ Time Frame: Day 0 (inclusion) , Day 7 and Day 28 ]
    Pain score and prurit will be assessed at D0, D7 and D28 using a 100 Visual Analogue Scale [Visual analogue scale , 0 (no pain, no prurit) and 100 (worst possible pain or prurit)]

  8. Assessment of the repair quality of skin [ Time Frame: Day 0 (inclusion) , Day 7 and Day 28 ]
    The repair quality of skin will be assessed from D0, D7 and D28 using a standardized diary completed by subjects.

  9. Cosmetic parameters such as nourishing power of the cream will be assessed at D28 using a standardized diary [ Time Frame: 28 days ]
    Nourishing power will be assessed at D28 using a standardized diary completed by subjects.

  10. Cosmetic parameters such as soothing power of the cream will be assessed at D28 using a standardized diary [ Time Frame: 28 days ]
    Soothing power will be assessed at D28 using a standardized diary completed by subjects.

  11. Cosmetic parameters such as penetration power of the cream will be assessed at D28 using a standardized diary [ Time Frame: 28 days ]
    Penetration power will be assessed at D28 using a standardized diary completed by subjects.

  12. Assessment of compliance [ Time Frame: 28 days ]
    The compliance will be assessed at the end of the study: subject will be considered to be compliant if he/she applied at least the theoretical consumption of 60% of the product.

  13. The overall tolerance will be assessed by the investigator (Subject interrogation). This evaluation will be carried out during visits using the following rating: 1 = Very good tolerance 2 = Good tolerance 3 = Middle tolerance 4 = Poor tolerance [ Time Frame: 28 days ]
    1. = Very good tolerance: no functional signs of discomfort and no objective signs during examination
    2. = Good tolerance: some functional signs of minimal and transient discomfort that did not interrupt the applications and no objective signs during examination
    3. = Middle tolerance: functional signs of discomfort, net or persistent, or objective signs during examination that did not interrupt the applications of the investigationalproduct
    4. = Poor tolerance: functional and / or objectives signs leading to discontinuation of the use of the investigational product

  14. Safety will be will be evaluated in terms of: - the number of subjects presenting during the study period at least : One AE/ One SAE - the total number of AEs during the study period - the total number of SAEs during the study period [ Time Frame: 28 days ]
    Safety will be assessed on the basis of adverse event (AE) reports



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Who suffers from grade 2 HFS
  • Subject under anti-tumor treatment known to cause this toxicity: targeted therapies or conventional chemotherapy: 5-Fluorouracile, Aflibercept, Axitinib, Bévacizumab, Capécitabine, Cediranib, Cytarabine, Dabrafenib, Docétaxel, Doxorubicine, Epirubicine, Pazopanib, Sorafenib, Sunitinib, Trastuzumab, Regorafenib, Vemurafenib and any other anti-tumor treatment that may lead to this toxicity
  • Subject 18 years old and more
  • Subject having been informed, having signed a free, informed and written consent
  • Woman of childbearing age using contraception deemed effective

Non-Inclusion Criteria:

  • Pregnant or lactating women
  • Subject having a history of allergic contact dermatitis or irritation to any of the components of the investigational products
  • Subjects with another skin pathology that may interfere with the evaluation of a HFS (at the investigator's discretion)
  • Subject under anti-inflammatory treatment
  • Subject participating in another clinical study during the duration of the study, except in a study assessing one of the molecules listed in the section above
  • Subject who has already been treated for Grade 2 HFS or under other local treatment or cosmetic product
  • Subject refusing to interrupt the application of his/her usual care
  • Subject having a strongly altered general condition and / or non-autonomous subject (Karnofsky index <50%)
  • Subject in linguistic or psychic impossibility to understand and sign informed consent or in the impossibility of submitting to the medical follow-up of the study
  • Subject deprived of liberty by administrative or judicial decision, or under guardianship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03612011


Locations
Layout table for location information
France
Quanta Medical
Rueil-Malmaison, France, 92500
Sponsors and Collaborators
Quanta Medical
NAOS
Publications:
Layout table for additonal information
Responsible Party: Quanta Medical
ClinicalTrials.gov Identifier: NCT03612011    
Other Study ID Numbers: NAOS_ONCOREPAIR_PP_17_2851
First Posted: August 2, 2018    Key Record Dates
Last Update Posted: September 6, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Quanta Medical:
Hand Foot Syndrome Grade 2
Common Terminology Criteria for Adverse Events (CTCAE)
Oncology
Repair Cream
Cutaneous events
Palmar-plantar erythrodysesthesia syndrome
Targeted Therapies or Conventional Chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hand-Foot Syndrome
Syndrome
Disease
Pathologic Processes
Drug Eruptions
Dermatitis
Skin Diseases
Drug Hypersensitivity
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders